FP179BASELINE CHARACTERISTICS IN THE "CARDINAL" TRIAL: A PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME. (13th June 2019)